Table 1.
Clinical data characteristics of 908 patients after mastectomy before and after PSM
| Variable | Pre PSM | After PSM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N=908 | RT N=583(%) |
NRT N=325(%) |
χ2 value | P value | N=596 | RT N=298(%) |
NRT N=298(%) |
χ2 value | P value | ||
| Age, y | 13.025 | <0.001 | 0.883 | 0.347 | |||||||
| ≤40 | 119 | 94(79.0) | 25(21.0) | 44 | 19(43.2) | 25(56.8) | |||||
| >40 | 789 | 489(62.0) | 300(38.0) | 552 | 279(50.5) | 273(49.5) | |||||
| Tumor location | 0.099 | 0.753 | 0.275 | 0.600 | |||||||
| Outer | 615 | 397(64.6) | 218(35.4) | 402 | 204(50.7) | 198(49.3) | |||||
| Inner /central | 293 | 186(63.5) | 107(36.5) | 194 | 94(48.5) | 100(51.5) | |||||
| Histological grade | 10.830 | 0.013 | 1.367 | 0713 | |||||||
| I | 18 | 11(61.1) | 7(38.9) | 13 | 6(46.2) | 7(53.8) | |||||
| II | 447 | 273(61.1) | 174(38.9) | 300 | 150(50.0) | 150(50.0) | |||||
| III | 276 | 199(72.1) | 77(27.9) | 164 | 87(53.0) | 77(47.0) | |||||
| Unknown | 167 | 100(59.9) | 67(40.1) | 119 | 55(46.2) | 64(53.8) | |||||
| LVI | 11.226 | 0.001 | 0.065 | 0.798 | |||||||
| No | 537 | 321(59.8) | 216(40.2) | 381 | 192(50.4) | 189(49.6) | |||||
| Yes | 371 | 262(70.6) | 109(29.4) | 215 | 106(49.3) | 109(50.7) | |||||
| Ki-67,% | 5.262 | 0.022 | <0.001 | 1.000 | |||||||
| ≤30 | 465 | 282(60.6) | 183(39.4) | 312 | 156(50.0) | 156(50.0) | |||||
| >30 | 443 | 301(67.9) | 142(32.1) | 284 | 142(50.0) | 142(50.0) | |||||
| NRN | 2.028 | 0.154 | 1.170 | 0.279 | |||||||
| <10 | 23 | 18(78.3) | 5(21.7) | 14 | 9(64.3) | 5(35.7) | |||||
| ≥10 | 885 | 565(63.8) | 320(36.2) | 582 | 289(49.7) | 293(50.3) | |||||
| LNM | 65.787 | <0.001 | 0.910 | 0.634 | |||||||
| 1 | 427 | 219(51.3) | 208(48.7) | 351 | 170(48.4) | 181(51.6) | |||||
| 2 | 297 | 211(71.0) | 86(29.0) | 182 | 96(52.7) | 86(47.3) | |||||
| 3 | 184 | 153(83.2) | 31(16.8) | 63 | 32(50.8) | 31(49.2) | |||||
| ER/PR status | 4.409 | 0.036 | 0.885 | 0.347 | |||||||
| Positive | 726 | 454(62.5) | 272(37.5) | 483 | 237(49.1) | 246(50.9) | |||||
| Negative | 182 | 129(70.9) | 53(29.1) | 113 | 61(54.0) | 52(46.0) | |||||
|
HER-2 status |
13.878 | 0.001 | 3.216 | 0.200 | |||||||
| Negative | 558 | 350(62.7) | 208(37.3) | 373 | 179(48.0) | 194(52.0) | |||||
| Positive | 244 | 177(72.5) | 67(27.5) | 151 | 85(56.3) | 66(43.7) | |||||
| Unknown | 106 | 56(52.8) | 50(47.2) | 72 | 34(47.2) | 38(52.8) | |||||
| stagea | 0.079 | 0.778 | 0.007 | 0.935 | |||||||
| T1 | 419 | 267(63.7) | 152(36.3) | 275 | 137(49.8) | 138(50.2) | |||||
| T2 | 489 | 316(64.6) | 173(35.4) | 321 | 161(50.2) | 160(49.8) | |||||
Abbreviations aOnly including T stage; PSM: propensity score matching; RT: radiotherapy; NRT: non-radiotherapy; LVI: lymphovascular invasion; NRN: number of removed nodes; LNM: lymph node metastasis; ER/PR status: Estrogen Receptor/Progesterone Receptor; HER-2
Status: Human epidermal growth factor receptor 2